We are live on ! Find out more
P

Pfizer Portfolio holdings

AUM $170M Turnover 5.56%
1-Year Est. Return 191.09%
This Fund
S&P 500
This Quarter Est. Return
+21.95%
1 Year Est. Return
+191.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$576M
AUM Growth
+$75.4M
Cap. Flow
-$776K
Cap. Flow %
-0.13%
Top 10 Hldgs %
96.54%
Holding
21
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.4 years
Top 20 Avg Time Held
0.5 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$776K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BNTX icon
1
BioNTech
BNTX
$22.6B
$390M 67.6%
3,658,361
– –
2024 Q4
2 quarters
ORIC icon
2
Oric Pharmaceuticals
ORIC
$1.47B
$54.6M 9.47%
5,376,344
– –
2024 Q4
2 quarters
ARVN icon
3
Arvinas
ARVN
$502M
$25.4M 4.42%
3,457,815
– –
2024 Q4
2 quarters
ALLO icon
4
Allogene Therapeutics
ALLO
$463M
$24.9M 4.32%
22,032,040
– –
2024 Q4
2 quarters
TRML icon
5
DELISTED
Tourmaline Bio
TRML
$20.3M 3.53%
1,272,214
– –
2024 Q4
2 quarters
WVE icon
6
Wave Life Sciences
WVE
$670M
$12.2M 2.12%
1,875,000
– –
2024 Q4
2 quarters
PYXS icon
7
Pyxis Oncology
PYXS
$157M
$7.74M 1.34%
7,032,770
– –
2024 Q4
2 quarters
CRDF icon
8
Cardiff Oncology
CRDF
$75.5M
$7.6M 1.32%
2,411,575
– –
2024 Q4
2 quarters
BHVN icon
9
Biohaven
BHVN
$1.78B
$7.13M 1.24%
505,645
– –
2024 Q4
2 quarters
SPRO icon
10
Spero Therapeutics
SPRO
$69.3M
$6.85M 1.19%
2,362,348
– –
2024 Q4
2 quarters
CRBU icon
11
Caribou Biosciences
CRBU
$53.3M
$5.91M 1.03%
4,690,431
– –
2024 Q4
2 quarters
CELC icon
12
Celcuity
CELC
$3B
$4.66M 0.81%
349,406
– –
2024 Q4
2 quarters
ZURA icon
13
Zura Bio
ZURA
$402M
$3.12M 0.54%
2,970,022
– –
2024 Q4
2 quarters
EPIX icon
14
DELISTED
ESSA Pharma
EPIX
$2.85M 0.49%
1,675,000
– –
2024 Q4
2 quarters
ZNTL icon
15
Zentalis Pharmaceuticals
ZNTL
$226M
$1.11M 0.19%
953,834
– –
2024 Q4
2 quarters
NXTC icon
16
NextCure
NXTC
$27.2M
$870K 0.15%
13,137
-144,510
-92% -$776K
2024 Q4
2 quarters
ANTX icon
17
AN2 Therapeutics
ANTX
$133M
$758K 0.13%
715,295
– –
2024 Q4
2 quarters
QTTB icon
18
Q32 Bio
QTTB
$255M
$414K 0.07%
277,777
– –
2024 Q4
2 quarters
BOLT icon
19
Bolt Biotherapeutics
BOLT
$8.24M
$181K 0.03%
31,305
– –
2024 Q4
2 quarters
DNA icon
20
Ginkgo Bioworks
DNA
$691M
$32.9K 0.01%
2,928
– –
2024 Q4
2 quarters
SENS icon
21
Senseonics Holdings Inc
SENS
$440M
$20.7K ﹤0.01%
2,171
– –
2024 Q4
2 quarters

Similar funds

BDS
Banco de Sabadell Miami, Florida $170M AUM 26.61% 1-Year Est. Return
WBCM
Wilson & Boucher Capital Management Moraga, California $170M AUM 28.6% 1-Year Est. Return
NL
NDWM LLC La Jolla, California $170M AUM 17.06% 1-Year Est. Return
WA
WPG Advisers Baltimore, Maryland $170M AUM 33.45% 1-Year Est. Return
EWM
Evolution Wealth Management Fort Myers, Florida $170M AUM 19.89% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
GA
Gordian Advisors Tucson, Arizona $170M AUM 18.06% 1-Year Est. Return
SVP
Strategic Value Partners Greenwich, Connecticut $171M AUM

Pfizer's Q2 2025 Portfolio in Review

As of Q2 2025, Pfizer held 21 positions worth $576M, up 15% from $501M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Pfizer opened no new positions and made no exits, leaving the 21-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pfizer's biggest Q2 2025 reduction was NextCure, cutting an estimated $776K.
  • Pfizer's ten largest holdings make up 97% of its $576M portfolio in Q2 2025.
  • Pfizer opened 0 new positions and closed 0 in Q2 2025.
  • Pfizer's portfolio value rose 15% quarter-over-quarter to $576M.

Based on Pfizer's 13F filing for Q2 2025, filed 11 Aug 2025.